Meridian Bioscience, Inc. (VIVO) Misses Q4 EPS by 2c; Reaffirms FY12 Outlook
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $4.68 -5.65%
Financial Fact:
Total other income (expense): -143K
Today's EPS Names:
CRMT, More
Financial Fact:
Total other income (expense): -143K
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q4 EPS of $0.17, $0.02 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $40.27 million versus the consensus estimate of $43.29 million.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
